Dr. Pushkar Kanade, M.D
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 18
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 1,032
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
OH license 57.019018
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Great Plains Health North Platte, NE
- Community Hospital Mccook, NE
- Sidney Regional Medical Center Sidney, NE
- Citizens Medical Center Colby, KS
- Cherry County Hospital Valentine, NE
Medical groups
- North Platte Nebraska Hospital Corporation (243 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,032
- Services billed
- 4,764
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 1,129 | 248 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,055 | 603 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 423 | 61 |
| Established patient office or other outpatient visit, 20-29 minutes | 381 | 326 |
| Home dialysis services per month (20 years or older) | 234 | 30 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 224 | 189 |
| New patient office or other outpatient visit, 45-59 minutes | 209 | 209 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 82 | 45 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 66 | 51 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 47 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 13 payments worth $5,316 in total to this clinician.
| Ardelyx, Inc. | $4,500 |
|---|---|
| Amgen Inc. | $713 |
| Travere Therapeutics, Inc. | $50.36 |
| Calliditas Therapeutics US Inc. | $20.60 |
| Fresenius USA Marketing, Inc. | $16.98 |
| Ani Pharmaceuticals, Inc. | $14.74 |
| Compensation for services other than consulting (speaking, faculty) | $5,200 |
|---|---|
| Food and Beverage | $114 |
| Education | $1.66 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ardelyx, Inc. Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) XPHOZAH 30 MG · NEPHROLOGY | $1,500 |
| Ardelyx, Inc. Feb 4, 2025 | Compensation for services other than consulting (speaking, faculty) XPHOZAH 30 MG · NEPHROLOGY | $1,200 |
| Ardelyx, Inc. Feb 11, 2025 | Compensation for services other than consulting (speaking, faculty) XPHOZAH 30 MG · NEPHROLOGY | $1,200 |
| Ardelyx, Inc. Jan 16, 2025 | Compensation for services other than consulting (speaking, faculty) XPHOZAH 30 MG · NEPHROLOGY | $600 |
| Amgen Inc. Jun 16, 2025 | Compensation for services other than consulting (speaking, faculty) KRYSTEXXA · Inflammation/Rare Disease | $350 |
| Amgen Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) KRYSTEXXA · Inflammation/Rare Disease | $350 |
| Travere Therapeutics, Inc. Nov 12, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $362,983 in research payments for these studies, mostly to the institutions running them.
- A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease
Boehringer Ingelheim Pharma GmbH & Co.kg - A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease
Boehringer Ingelheim International GmbH - Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Csl Behring · Recruiting · NCT05485961
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.